JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
$248.24
arrow_upward
+1.14%(+2.81) 1D
$249.00
arrow_upward
+0.31% (+0.76)todayPre-market
Closed: Nov 11, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for JAZZ...
Open
$244.24
High
$248.97
Low
$243.76
Mkt. cap
15.93B
Avg. vol.
854.53K
Volume
1.18K
P/E ratio
80.78
52-wk high
$266.38
52-wk low
$136.27
EPS
$3.07
Beta
0.38
Shares outstanding
64.19M
No. of employees
3K
Open
$244.24
High
$248.97
Low
$243.76
Mkt. cap
15.93B
Avg. vol.
854.53K
Volume
1.18K
P/E ratio
80.78
52-wk high
$266.38
52-wk low
$136.27
EPS
$3.07
Beta
0.38
Shares outstanding
64.19M
No. of employees
3K
News stories
From web sources and news partners
Benzinga
·
21 hours ago
At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M
Yahoo Finance
·
2 days ago
S&P 500 Just Wiped Out $3 Trillion: Why This 0.35-Beta Stock is a Safe Haven
TradingView
·
3 days ago
Weekly Recap: Rare sleep outlook rises and 2026 revenue outlook raised
CMC Markets
·
6 days ago
JAZZ Stock Earnings Review: Don’t Be Misled by Jazz Pharmaceuticals’ Apparent Wipe-Out
Profile
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
About Jazz Pharmaceuticals PLC
CEOBruce C Cozadd
Employees2.89K
Founded2003
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitejazzpharma.com